Validated Sterility and Endotoxin Testing for ATMPs

PROVEN INTELLIGENCE IN ASEPTIC MANUFACTURING ANALYTICS.

Programmatic Asset

CELL & GENE | RNA | BIOLOGICS

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Executive Summary

For Advanced Therapy Medicinal Product (ATMP) developers targeting European approvals, sterility and endotoxin testing are foundational to the Investigational Medicinal Product Dossier (IMPD). Standard compendial methods are often incompatible with the short shelf-life of many cell-based or RNA-based next-generation therapeutics. This necessitates a strategic shift towards validated, rapid microbiological methods that satisfy MHRA and EMA expectations for product safety and support accelerated clinical timelines. Franklin Biolabs provides the GxP-compliant analytical framework to qualify and validate these phase-appropriate assays, ensuring batch release is both compliant and timely.

Frequently Asked Questions

What are the primary challenges in sterility testing for ATMPs submitted to the MHRA?

The main challenge is the conflict between the 14-day incubation period required by traditional compendial sterility tests (Ph. Eur. 2.6.1) and the limited shelf-life of many ATMPs, such as autologous CAR-T therapies. This requires the validation of rapid microbiological methods (RMMs) to provide timely data for batch release without compromising patient safety, a core requirement for IMPD submissions.

How does endotoxin testing for viral vectors differ from other biologics?

Viral vectors, particularly those produced in bacterial systems, can present unique challenges for Limulus Amebocyte Lysate (LAL) based endotoxin assays (Ph. Eur. 2.6.14). Components of the vector formulation or product matrix can interfere with the assay. Consequently, robust method development and product-specific validation are required to overcome potential inhibition or enhancement effects and ensure accurate detection of pyrogenic substances.

Are rapid microbiological methods (RMMs) accepted by European regulators for ATMP batch release?

Yes, regulatory bodies including the MHRA and EMA accept validated RMMs, provided the method is demonstrated to be equivalent or superior to the traditional compendial method. The validation package must be comprehensive, covering specificity, sensitivity, and robustness to support a parametric release strategy, which is often necessary for next-generation therapeutics with short viability windows.

Navigating Sterility Assurance for European ATMP Submissions

The aseptic processing of ATMPs presents distinct analytical hurdles. Many of these products, especially autologous cell therapies, have extremely short stability profiles that render the standard 14-day sterility test impractical for final product release. Awaiting results would mean the therapeutic is no longer viable.

This operational reality demands a forward-thinking analytical strategy aligned with European Pharmacopoeia (Ph. Eur.) and specific MHRA guidelines. The focus shifts from end-product testing alone to a holistic approach encompassing:

  • Rigorous validation of the aseptic manufacturing process.

  • Comprehensive environmental monitoring programs.

  • Qualification of rapid methods for faster time-to-result.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

Method Validation for Rapid Release

For ATMP developers targeting UK and EU clinical trials, the IMPD must contain a robust justification for the chosen sterility and endotoxin testing methods. Franklin Biolabs develops and validates phase-appropriate analytical strategies that meet these regulatory expectations.

Assay Type Traditional Method (Ph. Eur.) Rapid Method Approach Regulatory Consideration
Sterility Ph. Eur. 2.6.1 (Direct Inoculation/Membrane Filtration) Growth-based (e.g., BacT/ALERT) or Viability-based (e.g., ATP bioluminescence) Validation must prove equivalency to the compendial method to support release of products with <14 day shelf-life.
Endotoxin Ph. Eur. 2.6.14 (LAL Gel-clot, Turbidimetric, Chromogenic) Recombinant Factor C (rFC) Assays Reduces reliance on animal-derived reagents and can mitigate assay interference from product components.

The successful translation of complex in vivo modalities, such as the genome editing platforms demonstrated in nonhuman primate models (PMID: 29985478), depends entirely on this foundation of rigorous CMC analytics. The sterility and pyrogen-free status of a vector batch is a foundational component of the safety profile required for clinical evaluation. Our GxP-compliant analytical laboratories, housed within our >100,000 sq ft facilities, are designed to execute these precise validation studies.

This analytical rigor is a core component of the services provided within our Vector | CMC | Analytics Services pillar, ensuring that manufacturing processes yield a product that is safe for clinical use.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities